| Literature DB >> 25089121 |
Frode Lindemark1, Ole Frithjof Norheim1, Kjell Arne Johansson1.
Abstract
BACKGROUND: Resource allocation decisions currently lack standard quantitative methods for incorporating concerns about the worse off when analysing the cost-effectiveness of medical interventions.Entities:
Keywords: Equity; Healthcare rationing; Priority setting in health; Quality-adjusted life years; Severity
Year: 2014 PMID: 25089121 PMCID: PMC4118218 DOI: 10.1186/1478-7547-12-16
Source DB: PubMed Journal: Cost Eff Resour Alloc ISSN: 1478-7547
Figure 1Representation of the QALY concept in a lifetime perspective.
Condition-intervention pairs ranked in order of gain in QALYs
| 8 | 30.5 | 10.7 | (3.9) | High-cost, low-volume health care intervention. To date, relatively few patients have been considered eligible for a cochlear implant. Cochlear implantation has become an established routine treatment option for profoundly deaf adults and children who do not benefit from acoustic hearing aids both in Norway and around the world. | HTA | Bond 2009 [ | |
| (unilateral cochlear implant vs hearing aid and waiting list for implant) | |||||||
| 50 | 23.9 | 6.4 | (3.6) | High-risk patient with symptomatic aneurysm produces subarachnoid haemorrhage (SAH) with substantial rate of mortality (30-60%) and permanent disability (15-30%). Over the years, there has been debate about which unruptured aneurysm to treat. | CUA | Johnston 1999 [ | |
| (Coiling vs. no treatment) | |||||||
| 48 | 28.2 | 5.2 | (2.3) | Increasing public health problem in Norway and elsewhere. Increased risk of premature death and reduced quality of life due to obesity-related co-morbidities. Potential demand for bariatric surgery is greater than availability. | HTA | Klarenbach 2010 [ | |
| (RY gastric bypass vs. lifestyle modification: diet and exercise medical counselling) | |||||||
| 50 | 14.0 | 4.2 | (2.4) | See childhood deafness | HTA | Bond 2009 [ | |
| (Unilateral cochlear implant implant for adult) | |||||||
| 52 | 17.3 | 2.3 | (1.4) | Uncertainty about the intervention‘s long-term effects on stroke risk, mortality and QoL, but already established as an attractive alternative to drug-refractory AF in symptomatic patients with recurrent AF. Waiting list 0.5-1 year in Norway. Causes patients to pursue treatment abroad, some at their own cost. | CUA | McKenna 2009 [ | |
| (Catheter ablation vs. antiarrhythmic drug therapy | |||||||
| 63 | 19.8 | 1.3 | (0.9) | High-volume, relatively high-cost intervention. Five thousand hip arthroplasties per year. Half of the adult population at risk. | CUA | Rasanen 2007 [ | |
| (Hip replacement vs. nonoperative approach) | |||||||
| 55 | 6.1 | 1.3 | (1.0) | 20 000–30 000 patients in Norway. Lifelong burden of pain, discomfort and physical impairment; the years of life lost are estimated to be 5–7 years. In Norway, at least one DMARD has to be tried before prescribing biological agents such as TNF inhibitors on the grounds of the higher cost of biological agents, although combination therapy with a TNF inhibitor is more effective in treating rheumatoid arthritis. | HTA | Chen 2006 [ | |
| (TNF inhibition + methotrexate vs. Methotrexate) | |||||||
| 70 | 6.4 | 0.5 | (0.3) | Approximately 15 000 cases annually in Norway and is the third most common cause of death; it is a major cause of severe disability and accounts for a significant proportion of healthcare spending. Over the past years, there has been a focus on developing stroke units at hospitals around the country. | HTA | Hamidi 2010 [ | |
| (Stroke unit vs. general ward) | |||||||
*Average age (years) at the time of intervention.
†Expected remaining quality-adjusted life years given a certain disease with standard care. Undiscounted data. Utilities expressing the current severity can be found in Additional file 2.
‡Undiscounted data. The discounted gain in QALYs is shown in brackets. Note that the annual discount rates vary between the source studies [see Additional file 2]. Ranking according to the discounted gains in QALYs would yield a different order.
Abbreviations: AF atrial fibrillation, CUA cost-utility analysis, DMARD disease-modifying antirheumatic drug, QoL quality of life, HTA health technology assessment, QALY quality-adjusted life year, RY roux-en-y, TNF tumour necrosis factor.
Figure 2Ranking according to lifetime QALYs (age + QALE) for eight condition-intervention pairs. Childhood deafness had the worst prognosis (top) and hip osteoarthritis had the best prognosis (bottom) from a lifetime perspective. Abbreviations: QALEstd, remaining quality-adjusted life years given a certain disease treated with standard care; QALY, quality-adjusted life year; RY, roux-en-y; TNF, tumour necrosis factor.
Figure 3Ranking of conditions according to proportional shortfall of QALYs. Patients with rheumatoid arthritis and acute stroke were worst off and patients with hip osteoarthritis and morbid obesity were best off. For each condition, the total length of the bar represents the remaining QALYs in absence of illness (QALEN). The red part of the bar represents the absolute shortfall of QALYs due to illness. Abbreviations: QALEstd, remaining quality-adjusted life years given a certain disease treated with standard care; QALY, quality-adjusted life year; RY, roux-en-y; TNF, tumour necrosis factor.
Figure 4The condition-interventions pairs ranked according to the net health gain from the intervention. Unilateral cochlear implant to deaf children was most effective, and stroke units for acute stroke victims were least effective. Abbreviations: QALY, quality-adjusted life year; TNF, tumour necrosis factor; RY, roux-en-y.